[{"id":"bc627950-fdba-45ae-9e4f-5fa0f5be6e30","acronym":"PLAT-05","url":"https://clinicaltrials.gov/study/NCT03330691","created_at":"2021-01-18T16:26:51.398Z","updated_at":"2024-07-02T16:35:31.304Z","phase":"Phase 1","brief_title":"A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia","source_id_and_acronym":"NCT03330691 - PLAT-05","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCRI-CAR19x22v2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 11/03/2017","start_date":" 11/03/2017","primary_txt":" Primary completion: 09/13/2023","primary_completion_date":" 09/13/2023","study_txt":" Completion: 03/03/2035","study_completion_date":" 03/03/2035","last_update_posted":"2023-10-27"}]